OncLive Staff

The FDA has accepted a new drug application for tivozanib for the treatment of patients with relapsed/refractory renal cell carcinoma.

In our exclusive interview, Dr. Karlan shares the rewarding moments and challenges she has encountered in the cancer space as a female oncologist, pivotal research she has been spearheaded that has lasting impacts on the field, and other developments in gynecologic cancers that are poised to change the landscape forever.

The FDA has granted a Fast Track designation to CLR 131 for use as a treatment for patients with lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia.

Howard A. "Skip" Burris, III, MD, FASCO, FACP, and Stephanie L. Graff, MD, discuss how the COVID-19 pandemic has affected cancer care, the collaborative efforts made between Sarah Cannon Research Institute and HCA to increase access to investigational COVID-19 treatments, and the steps ASCO has taken to ensure its members’ professional education and well-being during this time.

In our exclusive interview, Maria-Victoria Mateos, MD, PhD, discusses the FDA approval of the subcutaneous daratumumab formulation in multiple myeloma.

In our exclusive interview, Maria-Victoria Mateos, MD, PhD, discusses the FDA approval of the subcutaneous daratumumab formulation in multiple myeloma.

Manuel Hidalgo Medina, MD, PhD, discusses some of the exciting research presented at the 2020 ACCR Virtual Annual Meeting I.

Jennifer Litton, MD, discusses the findings from the overall survival analysis of the EMBRACA trial, the implications of these data, and the future utility of talazoparib in this space.

Bradley McGregor, MD, discusses the purpose of the guidelines, some of the main factors that influenced the recommendations in genitourinary cancers, and the impact of the pandemic on some of the most common treatment interventions such as immunotherapy, chemotherapy, and hormonal therapy, for patients with these malignancies.

Warner K. Huh, MD, discusses some of the key challenges faced in the management of gynecologic cancers in light of the COVID-19 crisis, shares some of the resources provided by the SGO COVID-19 task force, and projects what is needed to quell the pandemic, which he refers to as version of the Great Depression.

In our exclusive interview, Thomas Herzog, MD, discusses the FDA approval of the combination of olaparib (Lynparza) and bevacizumab (Avastin) as frontline maintenance therapy in HRD-positive advanced ovarian cancer.

In our exclusive interview, Thomas Herzog, MD, discusses the FDA approval of the combination of olaparib (Lynparza) and bevacizumab (Avastin) as frontline maintenance therapy in advanced ovarian cancer. 

Jonathan C. Trent, MD, PhD, sheds light on the impact of COVID-19 on the treatment of rare cancers.

Nina Shah, MD and Sandy Wong, MD, discuss the predictive value of minimal residual disease and the need for treatment in a patient with smoldering multiple myeloma.

Nina Shah, MD and Sandy Wong, MD, discuss the predictive value of minimal residual disease and the need for treatment in a patient with smoldering multiple myeloma.

We recently traveled to Miami, Florida for a State of the Science Summit™ on Gastrointestinal Malignancies, which featured insights from Florida Society of Clinical Oncology faculty.

Nabil F. Saba, MD, FACP, discusses how the COVID-19 pandemic has impacted treatment in head and neck cancer and the health care system at large.

Allyson Ocean, MD, discusses the emotional toll COVID-19 has had on patients and practitioners in the oncology space and the importance of self-care and social distancing.

Aakash Desai, MD, MPH, provides additional insight into his research on COVID-19 risk and patients with cancer and shed light on how institutions are taking action against the virus.

In an effort to share some of the evolving knowledge about COVID-19 and how it is impacting the healthcare system on a global scale, the Uromigos group discusses statistics, strategies, and new studies as they relate to COVID-19 and patients with genitourinary cancers.

Ruth O’Regan, MD, provides insight on how the COVID-19 crisis is impacting the care of patients with breast cancer.

In our exclusive interview, Dr. Hortobagyi shares his journey in the development of anthracyclines and taxanes, biphosphonates, and gene therapies in breast cancer, some of the challenges he has encountered along the way, and what he hopes to tackle in the rest of his monumental career.

Naval G. Daver, MD, discusses the impact of COVID-19 on stem cell transplant for patients with hematologic malignancies and other measures put into place to prevent patients from infection.

Hyman B. Muss, MD, sheds light on how the COVID-19 pandemic is impacting elderly patients with breast cancer and explains why geriatric patients are at a heightened risk of developing severe complications from the virus.

In our exclusive interview, Aditya Bardia, MD, discusses the FDA approval of sacituzumab govitecan (Trodelvy) in metastatic triple-negative breast cancer.

Gilberto De Lima Lopes, MD, discusses how he navigates challenges caused by COVID-19 to continue to provide optimal care to his patients with cancer.

We recently traveled to Columbus, Ohio for a State of the Science Summit™ on Ovarian Cancer, which featured insights from The Ohio State University Comprehensive Cancer Center–James faculty.

Rashmi Murthy, MD, MBE, discusses the data that led to the approval of the tucatinib triplet, the clinical implications of the approval on practice, and the next steps for research with the agent.

Toni K. Choueiri, MD, discusses the COVID-19 and Cancer Consortium, a multicenter effort to obtain evidence-based information on patients with cancer who have tested positive for the virus.

Jyoti D. Patel, MD and Lawrence E. Feldman, MD, discuss second-line therapy in extensive-stage small cell lung cancer and the need for consolidative radiation, as well as the optimal sequence of therapy for a patient with non–small cell lung cancer who harbors a MET exon 14 mutation.